Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease

Arch Bronconeumol. 2024 Apr;60(4):226-237. doi: 10.1016/j.arbres.2024.01.013. Epub 2024 Feb 1.
[Article in English, Spanish]

Abstract

Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) frequently coexist, increasing the prevalence of both entities and impacting on symptoms and prognosis. CVD should be suspected in patients with COPD who have high/very high risk scores on validated scales, frequent exacerbations, precordial pain, disproportionate dyspnea, or palpitations. They should be referred to cardiology if they have palpitations of unknown cause or angina pain. COPD should be suspected in patients with CVD if they have recurrent bronchitis, cough and expectoration, or disproportionate dyspnea. They should be referred to a pulmonologist if they have rhonchi or wheezing, air trapping, emphysema, or signs of chronic bronchitis. Treatment of COPD in cardiovascular patients should include long-acting muscarinic receptor antagonists (LAMA) or long-acting beta-agonists (LABA) in low-risk or high-risk non-exacerbators, and LAMA/LABA/inhaled corticosteroids in exacerbators who are not controlled with bronchodilators. Cardioselective beta-blockers should be favored in patients with CVD, the long-term need for amiodarone should be assessed, and antiplatelet drugs should be maintained if indicated.

Keywords: Cardiopulmonary risk; Cardiovascular disease; Chronic obstructive pulmonary disease; Comorbidities; Exacerbations.

Publication types

  • Practice Guideline

MeSH terms

  • Administration, Inhalation
  • Adrenal Cortex Hormones / therapeutic use
  • Adrenergic beta-2 Receptor Agonists / therapeutic use
  • Bronchodilator Agents / therapeutic use
  • Cardiovascular Diseases* / complications
  • Drug Therapy, Combination
  • Dyspnea
  • Humans
  • Muscarinic Antagonists / therapeutic use
  • Pain / drug therapy
  • Pulmonary Disease, Chronic Obstructive* / drug therapy

Substances

  • Muscarinic Antagonists
  • Adrenal Cortex Hormones
  • Adrenergic beta-2 Receptor Agonists
  • Bronchodilator Agents